A Phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3369-3378

  Villalona Calero, Miguel A ^a,d   Petit, Thierry ^a   Kuhn, John ^a   Cobb, Patrick ^b   Kraynak, Maura ^a   Eckhardt, S Gail ^a   Drengler, Ronald ^a   Simmons, Cecelia ^a   Santabarbara, Pedro ^c   Von Hoff, Daniel D ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c Ilex Oncology Inc   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISNATOL MESYLATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHRYSENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROPYLENE GLYCOLS; PULMONARY EMBOLISM; THROMBOCYTOPENIA;

EID: 0032713109     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bair, K., Andrews, C., Tuttle, R., Knick, V., Mckee, D., and Cory, M. Biophysical studies and murine antitumor activity of arylmethylaminopropanediols (AMAP), a new class of DNA binding drugs. Proc. Am. Assoc. Cancer Res., 27: 424, 1986.
2. Everitt, B., Grebe, G., Mackars, A., Macklin, A., Whisnant, J., and Tuttle, R. Comparative pharmacology and toxicology of three arylmethylaminopropanediols (AMAPs): BWA770U, BW A773U, and BW A502U. Proc. Am. Assoc. Cancer Res., 27: 424, 1986.
3. Knick, V., Tuttle, R., Bair K., and Von Hoff, D. Murine and human tumor stem cell activity of three candidate arylmethylaminopropanediols (AMAP). Proc. Am. Assoc. Cancer Res., 27: 424, 1986.
4. Bellamy, W., Dorr, R., Bair, K., and Alberts, D. Cytotoxicity and mechanism of action of 3 arylmethylaminopropanediols (AMAPS). Proc. Am. Assoc. Cancer Res., 30: 562, 1989.
5. Carter, C., and Bair, K. Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells. Proc. Am. Assoc. Cancer Res., 30: 562, 1989.
6. Adams, D., Knick, V., Clendenin, N., Bair, K., and Tuttle, R. BW A770U: an antitumor DNA intercalator that displays limited and nonpleiotropic cross-resistance to other antitumor agents. Proc. Am. Assoc. Cancer Res., 28: 300, 1987.
7. Adams, D. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res., 49: 6615-6620, 1989.
8. Adams, D., Wilson, J., and Tuttle, R. Uptake, efflux, and cellular distribution of BW A770U, an arylmethylaminopropanediol (AMAP) DNA intercalator. Proc. Am. Assoc. Cancer Res., 28: 335, 1987.
9. Patel, D., Woolley, J., Shockcor, J., and Taylor, L. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab. Dispos., 19: 491-497, 1991.
10. Patel, D., Shockcor, J., Chang, S., Sigel, C., and Huber, B. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem. Pharmacol., 42: 337-346, 1991.
11. Harman, G., Craig, J., Kuhn, J., Luther, J., Turner, J., Weiss, G., Tweedy, D., Koeller, J., Tuttle, R., Lucas, V., Wargin, W., Whisnant, J., and Von Hoff, D. Phase I and clinical pharmacology trial of crisnatol (BWA 77OU mesylate) using a monthly single-dose schedule. Cancer Res., 48: 4706-4710, 1988.
12. Cobb, P., Havlin, K., Kuhn, J., Craig, J., Harman, G., Luther, J., Turner, J., Weiss, G., Tweedy, D., Koeller, J., Tuttle, R., Lucas, V., Wargin, W., Whisnant, J., and Von Hoff, D. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. Sel. Cancer Ther., 7: 85-91, 1991.
13. Poplin, E., Chabot, G., Tuttle, R., Lucas, V., and Baker, L. Crisnatol mesylate: Phase I dose escalation by extending infusion duration. Invest. New Drugs, 9: 41-47, 1991.
14. New, P., Vokes, E., Rogers, L., Bazan, C., Hohneker, J., Eble, M., and Vilk, P. Long-term response to crisnatol mesylate in patients with glioma. Invest. New Drugs, 15: 343-352, 1997.
15. National Cancer Institute Division of Cancer Treatment. Guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1988.
16. Gibaldi, M., and Perrier, D. One compartment model. In: M. Gibaldi and D. Perrier (eds.), Pharmacokinetics, Ed 2, pp. 27-31. New York: Marcel Dekker, Inc., 1992.
17. Smalley, R., Goldstein, D., Bulkowski, D., Hannon, C., Buchler, D., Knudsen, C., and Tuttle, R. A Phase II study of crisnatol mesylate in patients with ovarian carcinoma. Invest. New Drugs, 10: 107-112, 1992.
18. Fleishaker, J., Pearson, L., and Peters, G. Phenytoin causes a rapid increase in 6 β-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J. Pharm. Sci., 84: 292-294, 1995.
19. Fetell, M., Grossman, S., Fisher, J., Erlanger, B., Rowinsky, E., Stockel, J., and Piantadosi, S. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology and drug interactions. J. Clin. Oncol., 15: 3121-3128, 1997.
20. Chang, S., Kuhn, J., Rizzo, J., Robins, H., Schold, S., Spence, A., Berger, M., Mehta, M., Bozik, M., Pollack, I., Gilbert, M., Fulton D., Rankin, C., Malck, M., and Prados, M. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol., 16: 2188-2194, 1998.
21. Ruff, R., and Posner, J. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann. Neurol., 13: 334-336, 1983.
22. Brandes, A., Scelzi, E., Salmistraro, G., Ermani, M., Carollo, C., Berti, F., Zampieri, P., Baiocchi, C., and Fiorentino, M. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur. J. Cancer, 33: 1592-1596, 1997.
23. Komp, D., Lyles, R., Boyd, T., Stoner, G., and Cox, B. The effect of cancer chemotherapeutic agents in fibrin formation and stabilization in vitro. Pediatr. Res., 8: 75-81, 1974.
24. Bick, R., Fekete, L., and Wilson, W. Doxorubicin and fibrinolysis. Thromb. Res., 8: 467-475, 1976.
25. Bick, R., Fekete, L., and Wilson, W. Daunorubicin and fibrinolysis. Thrombosis Res., 9: 201-209, 1976.
26. Priest, J., Ramsay, N., Steinherz, P., Tubergen, D., Cairo, M., Sitarz, A., Bishop, A., White L., Trigg, M., Levitt, C., Cich, J., and Coccia, P. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia, J. Pediatr., 100: 984-989, 1982.